WilmerHale Advises Verve Therapeutics in Global Collaboration with Eli Lilly and Company

WilmerHale Advises Verve Therapeutics in Global Collaboration with Eli Lilly and Company

Client News

Related Solutions

Leveraging regulatory and corporate experience to solve legal challenges for defense tech companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.

On June 15, 2023, Verve Therapeutics announced a research collaboration with Eli Lilly and Company (Lilly) focused on advancing Verve’s preclinical stage in vivo gene editing program targeting lipoprotein(a) (Lp(a)). Elevated Lp(a) is an established and genetically validated, independent risk factor for atherosclerotic cardiovascular disease (ASCVD), ischemic stroke, thrombosis and aortic stenosis. Under the terms of the agreement, Verve will advance the research and development of the Lp(a) program through the completion of Phase 1 clinical development. Verve will receive an upfront payment of $60 million, including a $30 million equity investment. Verve’s program cost through Phase 1 clinical trials will be funded by Lilly, and Verve is eligible to receive research, development, and commercial milestones, as well as tiered royalties on global net sales.

The WilmerHale team representing Verve in the collaboration with Lilly was led by Sarah Hogan and Scott Forman. The WilmerHale team representing Verve in the equity investment by Lilly was led by Craig Hilts, Andrea Sorrentino and Alex Bloom.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel